crIpeC nAnomedicines’ micRodistribution in tUmour tiSsue

ended

Cristal Therapeutics (CT) is an innovative SME based in the Netherlands dedicated to the creation of the next generation of targeted nanomedicines (NM). CT has developed CriPec, a nanoparticle technology that can entrap a wide range of drugs, transforming them into custom-made NM. CriPec-based products have demonstrated excellent pharmacokinetics and tumour accumulation as well as highly improved safety, both in laboratory and patient settings. However, the full therapeutic potential of CriPec has not been obtained due to a lack of understanding of its tumour microenvironment (TME) microdistribution and behaviour, hindered by the lack of highly specific (bio)analytical expertise within Cristal Therapeutics. ICARUS will enable CT to solidify its position as an innovative SME and provide them a competitive edge through hiring an Innovation Associate (IA). The envisioned IA will develop and implement state-of-art (bio)analytical methodologies (including advanced MALDI-techniques) that have not been exploited in the field of NM until now, and that will provide CT with essential insights that will guide the composition optimisation of all CriPec-based products. Furthermore, the ICARUS project is heavily focused around the training of the IA, thereby greatly improving his/her career development. A training programme tailored to his/her specific needs and personal career development plan will be developed, allowing the IA to: • Gain novel skills and experience on every aspect of the development of nanoparticles, encompassing the required multidisciplinary expertise from several fields; • Gain innovation and business related skills in a multidisciplinary setting.